Full Title
A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant Solid TumorsPurpose
Researchers want to find the best dose of LY4066434 when given alone and with other drugs to treat solid tumors. The people in this study have cancer that has spread (advanced) or cannot be removed with surgery (inoperable). These include colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, and other solid tumors.
In addition, their tumors have a mutation (change) in the KRAS gene, which can cause normal cells to become cancer. LY4066434 targets the mutant KRAS protein and prevents it from sending signals to tell cancer cells to grow and spread. In this way, LY4066434 may help slow or stop the growth of your cancer. It is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have advanced or inoperable colorectal cancer, pancreatic cancer, NSCLC, or other solid tumor with a KRAS mutation.
- Have recovered from the serious side effects of prior anti-cancer therapies before taking LY4066434.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Rona Yaeger’s office at 646-888-5109.